Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.
Article CAS PubMed Google Scholar
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
Cabasag CJ, Arnold M, Rutherford M, Bardot A, Ferlay J, Morgan E, et al. Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. Br J Cancer. 2022;126:1774–82.
Article PubMed PubMed Central Google Scholar
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Prim. 2016;2:16022.
Feng Y, Cai L, Pook M, Liu F, Chang C-H, Mouti MA, Nibhani R, Militi S, Dunford J, Philpott M, Fan Y, Fan G-C, Liu Q, Qi J, Wang C, Hong W, Morgan H, Wang M, Sadayappan S, Jegga AG, Oppermann U, Wang Y, Huang W, Jiang LPS. BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma. Gastroenterology. 2023;166:139–54.
Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021;48:10–8.
Article CAS PubMed PubMed Central Google Scholar
Akkapeddi P, Hattori T, Khan I, Glasser E, Koide A, Ketavarapu G, et al. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors. Proc Natl Acad Sci. 2023;120: e2302485120.
Article CAS PubMed PubMed Central Google Scholar
Mahadevan KK, LeBleu VS, Ramirez EV, Chen Y, Li B, Sockwell AM, et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Dev Cell. 2023;58:1562-1577.e8.
Article CAS PubMed Google Scholar
Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell. 2023;41:1606-1620.e8.
Article CAS PubMed Google Scholar
Pan M, Jiang C, Zhang Z, Achacoso N, Alexeeff S, Solorzano AV, et al. TP53 gain-of-function and non–gain-of-function mutations are associated with differential prognosis in advanced pancreatic ductal adenocarcinoma. JCO Precis Oncol. 2023;7: e2200570.
Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci. 2010;107:246–51.
Article CAS PubMed Google Scholar
Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527–40.
Article PubMed PubMed Central Google Scholar
Lennon AM, Wolfgang CL, Canto MI, Klein AP, Herman JM, Goggins M, et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res. 2014;74:3381–9.
Article CAS PubMed PubMed Central Google Scholar
Foster DS, Jones RE, Ransom RC, Longaker MT, Norton JA. The evolving relationship of wound healing and tumor stroma. JCI Insight. 2018;3: e99911.
Article PubMed PubMed Central Google Scholar
Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res. 2015;3:1–11.
Article CAS PubMed PubMed Central Google Scholar
Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019;12:126.
Article PubMed PubMed Central Google Scholar
Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619:707–15.
Article CAS PubMed Google Scholar
Ramezani F, Panahi Meymandi AR, Akbari B, Tamtaji OR, Mirzaei H, Brown CE, et al. Outsmarting trogocytosis to boost CAR NK/T cell therapy. Mol Cancer. 2023;22:183.
Article CAS PubMed PubMed Central Google Scholar
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21.
Article CAS PubMed PubMed Central Google Scholar
Uslu U, Da T, Assenmacher C-A, Scholler J, Young RM, Tchou J, et al. Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. Sci Adv. 2023;9:02526.
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang W-T, Vogl DT, Waxman AJ, et al. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov. 2023;4:118–33.
Article CAS PubMed Google Scholar
Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy—current perspectives and future directions. Cell. 2023;186:1652–69.
Article CAS PubMed Google Scholar
Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273–90.
Article CAS PubMed PubMed Central Google Scholar
Farhangnia P, Mollazadeh Ghomi S, Mollazadehghomi S, Delbandi A-A. Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment. Cham: Springer; 2023. p. 1–54.
Zheng L, Ding D, Edil BH, Judkins C, Durham JN, Thomas DL II, et al. Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma. Clin Cancer Res. 2021;27:1278–86.
Article CAS PubMed Google Scholar
Pihlak R, Weaver JMJ, Valle JW, McNamara MG. Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy. Cancers (Basel). 2018;10:17.
Riquelme E, Maitra A, McAllister F. Immunotherapy for pancreatic cancer: more than just a gut feeling. Cancer Discov. 2018;8:386–8.
Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, et al. The immune microenvironment in pancreatic cancer. Int J Mol Sci. 2020;21:7307.
Article CAS PubMed PubMed Central Google Scholar
Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, et al. Pancreatic cancer and immunotherapy: a clinical overview. Cancers (Basel). 2021;13:4138.
Article CAS PubMed Google Scholar
Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021;14:14.
Article PubMed PubMed Central Google Scholar
Chen J, Xiao-Zhong G, Qi X-S. Clinical outcomes of specific immunotherapy in advanced pancreatic cancer: a systematic review and meta-analysis. J Immunol Res. 2017;2017:8282391.
留言 (0)